RIYADH, Saudi Arabia, March 2025 — Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, has appointed Osama Braiwish as General Manager for Saudi Arabia and Gulf Countries. In this role, Braiwish will oversee operations across Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan, focusing on expanding access to innovative therapies and driving strategic healthcare partnerships.
“I’m incredibly proud to join Bristol Myers Squibb,” said Osama Braiwish. “BMS is deeply committed to driving innovation and transforming patients’ lives through science. The evolving healthcare landscape in the region uniquely positions us to enhance access to our groundbreaking therapies and make a difference in the lives of the communities we serve, particularly in areas of high unmet medical need such as hematology, oncology, and cardiovascular disease.”
As BMS expands its presence and treatment portfolio across key therapeutic areas, the company is committed to addressing pressing health challenges in the region. Braiwish emphasized the importance of building impactful collaborations within the healthcare sector to drive sustainable, long-term patient outcomes.
“We are very pleased to have Osama lead the team in Saudi Arabia and the Gulf Markets,” said Michelle Calope, Senior Vice President, Intercon Region for Bristol Myers Squibb. “This region represents an important part of our international strategy, and as General Manager, Osama is well positioned to drive growth, foster innovation, and cultivate an inclusive, high-performing team. We are pleased to see him lead our efforts to enhance access to cutting-edge therapies and strengthen partnerships that support sustainable healthcare outcomes in the region.”
Braiwish brings over 25 years of leadership experience in the pharmaceutical and diagnostics industry, along with deep market knowledge of Saudi Arabia, the Gulf, and the Levant region. Throughout his career, he has demonstrated a consistent ability to enhance patient access to advanced therapies, promote operational excellence, and build high-performing teams across diverse regions.
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases, including oncology, hematology, immunology, and cardiovascular conditions. With a mission to transform patients’ lives through science, BMS is committed to advancing medical breakthroughs and ensuring equitable access to life-changing therapies.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
